SHINKEI Therapeutics Email Format
Pharmaceutical ManufacturingNew Jersey, United States2-10 Employees
SHINKEI Therapeutics is a clinical-stage pharmaceutical company focused on central nervous system disorders. It employs a 505(b)2 regulatory strategy to repurpose existing pharmaceutical products for faster development and improved patient outcomes. Its product development pipeline seeks to improve drug administration to enable new indications, enhance convenience and adherence, and reduce adverse effects. The company was co-founded by Suresh Borsadia and GP Singh and is headquartered at 303a College Road East, Princeton, New Jersey 08540, United States, supported by a nimble and efficient team of professionals, advisors and consultants. Recent milestones include FDA clearance of the MR-101 IND for movement disorders in March 2026, and a 2019 IND filing for MR-201 for Pseudobulbar Affect (PBA); the company reports revenue in the range of $1 million to $10 million.